It has been shown that PD-L1 can be expressed on the surface of both tumor and immune cells, and the detection of its expression is a powerful biomarker to predict the response to anti-PD-1/PD-L1 therapies in patients with different malignancies [26]. This evidence concerns the gene CD274 and neoplasm.